AMD

See the results from our recent poll!

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

Vote in our most recent poll!

Advances in drug creation would reduce cost burden of treatment for patients.

See the results from our recent poll!

The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

Kicking off AMD Awareness Month, give us your thoughts!

Benefits include eliminating eyeglass problems and boosting patient confidence.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

As Baby Boomers enter the at-risk age group for vision loss, optometrists must be ready to act.

A multicenter US study revealed that the long-term use of metformin to treat diabetes and lifestyle changes in patients with diabetes were not associated with the risk of age-related macular degeneration (AMD).

As 2022 comes to a close, check out some of the hottest and most-liked stories from the year!

Look out for at-risk patients and prepare to establish treatment protocols.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.

Treatment suspension has negative impact on visual function.

AREDS2 formula doesn’t contain beta carotene, reducing the risk of lung cancer.

With the launch of dark adaptation, Heru is now the only platform on the AMD market to include contrast sensitivity and dark adaptation exams.

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

Korean investigators have found intermittent fasting may actually lead to a lower risk of developing AMD in the elderly population.

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

Advancements enable better diagnosis, treatment of patients.

Presented during the 2022 ASRS meeting, results find that over 60% of participants could be treated every 4 months at 2 years—an increase from 45% at year 1.

A decade after the conclusion of the NIH-funded AREDS2 study, researchers found that the AREDS2 formula also reduces the risk of lung cancer.

Trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.

Elena Biffi, OD, MSc, FAAO, dives into AMD, a multifactorial disease that requires a multimodal diagnostic imaging approach.

Embracing this new model of care can allow optometric practices to flourish—and may enable earlier detection of conversion from intermediate dry to wet AMD.

Early diagnosis and intervention are crucial when managing this patient base.